Besremi Shortage Update: What Patients Need to Know in 2026

If you've been hearing about drug shortages affecting polycythemia vera treatments, you're probably wondering where Besremi (Ropeginterferon Alfa-2b-njft) stands. The good news: Besremi is not on the FDA's official drug shortage list. The more complicated news: the broader interferon landscape has been disrupted, and that's affecting Besremi availability for some patients.

Here's everything you need to know about Besremi availability in 2026 — including what's causing the supply pressure, how much the drug costs, what new options may be on the horizon, and how to find it in stock.

Is Besremi Still in Shortage?

As of early 2026, Besremi is not formally listed on the FDA drug shortage database. However, patients and providers have reported sporadic difficulty accessing the medication through specialty pharmacies. The root cause isn't a problem with Besremi's own supply chain — it's the ripple effect of the Pegasys (Peginterferon Alfa-2a) shortage.

Here's what happened:

• 2021: Non-pegylated Interferon Alpha-2a was discontinued in the United States, reducing the available interferon options for PV patients
• 2024: Pegasys, a widely used off-label interferon for PV, entered a supply shortage
• January 2025: The NCCN updated its clinical practice guidelines to recommend substituting Besremi for Pegasys when unavailable
• March 2025: PharmaEssentia publicly highlighted Besremi's availability as an alternative for Pegasys-affected patients

The result? A significant wave of patients and providers turning to Besremi, which increased demand beyond what the supply chain was originally built for. PharmaEssentia has been scaling up production, but biologic manufacturing takes time.

Why Is Besremi Hard to Find?

Several factors make Besremi challenging to access, even though it's technically available:

• Specialty-only distribution: Besremi is only available through specialty pharmacies, not retail pharmacies like CVS or Walgreens
• Increased demand: Patients switching from Pegasys have significantly increased orders
• Prior authorization requirements: Most insurers require prior authorization, which can delay the process by days or weeks
• Step therapy: Some insurance plans require patients to try Hydroxyurea first before approving Besremi
• Complex biologic manufacturing: As a biologic, Besremi is produced using living cells, making rapid production scale-up difficult

For a detailed breakdown of these challenges, read our article on why Besremi is so hard to find.

How Much Does Besremi Cost in 2026?

Besremi is an expensive specialty medication. Here's what you can expect:

• Cash price (without insurance): Approximately $9,700 to $11,000 per injection (for a single prefilled syringe of 500 mcg/mL)
• With commercial insurance: Copays vary widely, but the PharmaEssentia SOURCE Copay Program can bring the cost to as little as $0 per month for eligible patients
• Medicare/Medicaid: Covered under most plans with prior authorization, but the copay assistance program is not available to federal program beneficiaries
• No generic available: Besremi is a biologic with no biosimilar or generic version on the market

For a complete guide to reducing your costs, read our article on how to save money on Besremi in 2026.

New Options on the Horizon

The polycythemia vera treatment landscape is evolving. Here are a few developments worth watching:

Rusfertide

Rusfertide is an investigational hepcidin mimetic being studied in Phase III clinical trials for PV. Unlike interferons or JAK inhibitors, it works by regulating iron metabolism to reduce red blood cell production. If approved, it could provide a completely new mechanism of action for PV patients. FDA approval is anticipated by late 2026.

Besremi Label Expansion

PharmaEssentia is pursuing an expanded FDA indication for Besremi to include essential thrombocythemia (ET). The NCCN has already included Ropeginterferon Alfa-2b as a Category 1 preferred regimen for ET, even ahead of formal FDA approval. A regulatory submission was expected by late 2025.

Ruxolitinib (Jakafi) Developments

Incyte continues to study Jakafi in combination therapies and new indications. While Jakafi doesn't reduce the JAK2 clone burden like Besremi, it remains an important option for PV patients who can't tolerate interferons.

How to Find Besremi in Stock

If you need Besremi now, here are your best options:

1. Use Medfinder

Medfinder helps you search specialty pharmacies for Besremi availability in real time. It's free and can save you hours of phone calls. For a detailed walkthrough, see our guide on how to find Besremi in stock near you.

2. Call PharmaEssentia SOURCE

PharmaEssentia's patient support program can help you locate pharmacies with stock, navigate insurance, and access financial assistance. Call 1-833-546-7473.

3. Ask Your Hematologist for Help

Your hematologist's office has direct relationships with specialty pharmacies and can often expedite the process. They may also know about local availability that isn't reflected in online databases.

4. Start Refills Early

Don't wait until the last minute. Begin the refill process at least 7 to 10 days before your next dose to account for insurance processing and shipping.

What If You Can't Get Besremi?

If there's going to be a gap in your supply, do not stop treatment without talking to your doctor. Your hematologist can:

• Increase phlebotomy frequency to keep your hematocrit under control
• Prescribe a bridging medication like Hydroxyurea
• Adjust your dosing schedule if you have partial supply

For a full list of treatment options, see our article on alternatives to Besremi.

Final Thoughts

The Besremi supply situation in 2026 is challenging but manageable. While the drug isn't in a formal shortage, increased demand from the Pegasys crisis has made it harder to access through specialty pharmacies. Prices remain high, but financial assistance programs can significantly reduce your out-of-pocket costs.

The most important things you can do: plan ahead, use tools like Medfinder to track availability, stay in close contact with your hematologist, and take advantage of PharmaEssentia's patient support programs. With new treatments on the horizon and expanded indications for Besremi, the outlook for PV patients is improving — even if the short-term access picture is complicated.